rs3817963

This is a intron variant variant in the BTNL2 gene.

GWAS Catalog Trait Associations (2)

Genome-wide significant associations (p < 5×10⁻⁸) from the NHGRI-EBI GWAS Catalog.

lung adenocarcinoma

Allele G
OR 1.29
p 1.0e-16
N 5,030
Large GWAS
East Asian
Allele G
OR 1.18
p 3.0e-10
N 7,028
Large GWAS
East Asian

Research that mentions this SNP (1)

Replication of genetic loci for sarcoidosis in US black women: data from the Black Women’s Health Study
AssociationN=1,429Yvette Cozier et al.(2013)· Human Genetics

Nested case-control study (486 cases, 943 controls) of African-American women from the Black Women's Health Study examining SNPs in the BTNL2 gene and ancestry informative markers for sarcoidosis susceptibility. The rs3817963 A-allele was associated with 40% increased sarcoidosis risk (p=0.02, OR=1.40), and rs30533 African ancestry was associated with 39-43% decreased risk (p=0.01). Higher global African ancestry was associated with 54% increased sarcoidosis risk in the highest quintile (p=0.03).

Traits studied:SarcoidosisSarcoidosis severity

About BTNL2

This gene encodes a major histocompatibility complex, class II associated, type I transmembrane protein which belongs to the butyrophilin-like B7 family of immunoregulators. It is thought to be involved in immune surveillance, serving as a negative T-cell regulator by decreasing T-cell proliferation and cytokine release. The encoded protein contains an N-terminal signal peptide, two pairs of immunoglobulin-like domains, separated by a heptad peptide sequence, and a C-terminal transmembrane domain. Naturally occurring mutations in this gene are associated with sarcoidosis, rheumatoid arthritis, ulcerative colitis, inflammatory bowel disease, myositis, type 1 diabetes, systemic lupus erythematosus, acute coronary syndrome, and prostate cancer. [provided by RefSeq, May 2017]

View all BTNL2 variants →

Gene information from NCBI Gene. Variant classifications from ClinVar.

Community Wiki

No community notes yet for this variant. Sign in to start one.

Comments

Sign in to join the discussion.

Loading comments…